{
    "language": "english",
    "relations": [
        {
            "sentence": "AMGen (formerly Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.",
            "subject": {
                "text": "AMGen (formerly Applied Molecular Genetics)"
            },
            "object": {
                "text": "an American multinational biopharmaceutical company headquartered in Thousand Oaks, California"
            },
            "action": {
                "text": "is",
                "lemmatized": "be",
                "verb": {
                    "text": "be",
                    "tense": "present"
                }
            }
        },
        {
            "location": {
                "text": "in Thousand Oaks, California"
            },
            "sentence": "AMGen (formerly Applied Molecular Genetics) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.",
            "subject": {
                "text": "an American multinational biopharmaceutical company"
            },
            "action": {
                "text": "headquartered",
                "lemmatized": "headquarter",
                "verb": {
                    "text": "headquarter",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases.",
            "subject": {
                "text": "the company's largest selling product lines"
            },
            "object": {
                "text": "Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy"
            },
            "action": {
                "text": "were",
                "lemmatized": "be",
                "verb": {
                    "text": "be",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases.",
            "subject": {
                "text": "two closely related drugs"
            },
            "object": {
                "text": "infections in patients undergoing cancer chemotherapy"
            },
            "action": {
                "text": "to prevent",
                "lemmatized": "to prevent",
                "verb": {
                    "text": "prevent",
                    "tense": "future"
                }
            }
        },
        {
            "location": {
                "text": "in the treatment of rheumatoid arthritis and other autoimmune diseases"
            },
            "sentence": " In 2013, the company's largest selling product lines were Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases.",
            "subject": {
                "text": "blocker"
            },
            "action": {
                "text": "used",
                "lemmatized": "use",
                "verb": {
                    "text": "use",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.",
            "subject": {
                "text": "Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA"
            },
            "object": {
                "text": "Other products"
            },
            "action": {
                "text": "include",
                "lemmatized": "include",
                "verb": {
                    "text": "include",
                    "tense": "present"
                }
            }
        },
        {
            "sentence": " The word AMGen is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering).",
            "subject": {
                "text": "the company's original name, Applied Molecular Genetics"
            },
            "object": {
                "text": "the official name of the company in 1983 (three years"
            },
            "action": {
                "text": "became",
                "lemmatized": "become",
                "verb": {
                    "text": "become",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988,[2] followed by Kevin W. Sharer in 2000.[3] Robert A. Bradway became Amgen\u2019s president and chief executive officer in May 2012 following Sharer's retirement.[4]",
            "subject": {
                "text": "The company's first chief executive officer, from 1980,"
            },
            "object": {
                "text": "co-founder George B. Rathmann"
            },
            "action": {
                "text": "was",
                "lemmatized": "be",
                "verb": {
                    "text": "be",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988,[2] followed by Kevin W. Sharer in 2000.[3] Robert A. Bradway became Amgen\u2019s president and chief executive officer in May 2012 following Sharer's retirement.[4]",
            "subject": {
                "text": "by Gordon M. Binder"
            },
            "action": {
                "text": "followed",
                "lemmatized": "follow",
                "verb": {
                    "text": "follow",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988,[2] followed by Kevin W. Sharer in 2000.[3] Robert A. Bradway became Amgen\u2019s president and chief executive officer in May 2012 following Sharer's retirement.[4]",
            "subject": {
                "text": "by Kevin W. Sharer"
            },
            "object": {
                "text": "Robert A. Bradway became Amgen\u2019s president and chief executive officer"
            },
            "action": {
                "text": "followed",
                "lemmatized": "follow",
                "verb": {
                    "text": "follow",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " The company has made at least five major corporate acquisitions.",
            "subject": {
                "text": "The company"
            },
            "object": {
                "text": "made at least five major corporate acquisitions"
            },
            "action": {
                "text": "has",
                "lemmatized": "have",
                "verb": {
                    "text": "have",
                    "tense": "present"
                }
            }
        },
        {
            "sentence": " The company has made at least five major corporate acquisitions.",
            "subject": {
                "text": "The company"
            },
            "object": {
                "text": "at least five major corporate acquisitions"
            },
            "action": {
                "text": "has made",
                "lemmatized": "have make",
                "verb": {
                    "text": "make",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " 1989. Amgen received approval for the first recombinant human erythropoetin product, Epogen, for the treatment of anemia associated with chronic kidney failure.",
            "subject": {
                "text": "1989. Amgen"
            },
            "object": {
                "text": "approval for the first recombinant human erythropoetin product, Epogen, for the treatment of anemia associated with chronic kidney failure"
            },
            "action": {
                "text": "received",
                "lemmatized": "receive",
                "verb": {
                    "text": "receive",
                    "tense": "past"
                }
            }
        },
        {
            "location": {
                "text": "under the tradename Procrit"
            },
            "sentence": " Epogen (also marketed by Johnson and Johnson under the tradename Procrit) would later be approved for anemia due to cancer chemotherapy, anemia due to treatment with certain HIV drugs, and for the reduction of the need for transfusions associated with surgery.[5]",
            "subject": {
                "text": "by Johnson and Johnson"
            },
            "object": {
                "text": "Epogen"
            },
            "action": {
                "text": "marketed",
                "lemmatized": "market",
                "verb": {
                    "text": "market",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " Epogen (also marketed by Johnson and Johnson under the tradename Procrit) would later be approved for anemia due to cancer chemotherapy, anemia due to treatment with certain HIV drugs, and for the reduction of the need for transfusions associated with surgery.[5]",
            "subject": {
                "text": "Epogen (also marketed by Johnson and Johnson under the tradename Procrit)"
            },
            "object": {
                "text": "approved for anemia"
            },
            "action": {
                "text": "be",
                "lemmatized": "be",
                "verb": {
                    "text": "be",
                    "tense": "future"
                }
            }
        },
        {
            "sentence": " Epogen (also marketed by Johnson and Johnson under the tradename Procrit) would later be approved for anemia due to cancer chemotherapy, anemia due to treatment with certain HIV drugs, and for the reduction of the need for transfusions associated with surgery.[5]",
            "subject": {
                "text": "Epogen (also marketed by Johnson and Johnson under the tradename Procrit)"
            },
            "object": {
                "text": "for anemia due to cancer chemotherapy, anemia due to treatment with certain HIV drugs"
            },
            "action": {
                "text": "approved",
                "lemmatized": "approve",
                "verb": {
                    "text": "approve",
                    "tense": "future"
                }
            }
        },
        {
            "sentence": " Epogen (also marketed by Johnson and Johnson under the tradename Procrit) would later be approved for anemia due to cancer chemotherapy, anemia due to treatment with certain HIV drugs, and for the reduction of the need for transfusions associated with surgery.[5]",
            "subject": {
                "text": "transfusions"
            },
            "object": {
                "text": "with surgery."
            },
            "action": {
                "text": "associated",
                "lemmatized": "associate",
                "verb": {
                    "text": "associate",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " 1991. In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[6] A 2002 meta-analysis found that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%.[7]",
            "subject": {
                "text": "Amgen"
            },
            "object": {
                "text": "FDA approval"
            },
            "action": {
                "text": "received",
                "lemmatized": "receive",
                "verb": {
                    "text": "receive",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " 1991. In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[6] A 2002 meta-analysis found that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%.[7]",
            "subject": {
                "text": "A 2002 meta-analysis"
            },
            "object": {
                "text": "that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%"
            },
            "action": {
                "text": "found",
                "lemmatized": "find",
                "verb": {
                    "text": "find",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " 1991. In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[6] A 2002 meta-analysis found that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%.[7]",
            "subject": {
                "text": "the risk of documented infection"
            },
            "object": {
                "text": "by 49%"
            },
            "action": {
                "text": "reduced",
                "lemmatized": "reduce",
                "verb": {
                    "text": "reduce",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " 1991. In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[6] A 2002 meta-analysis found that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%.[7]",
            "subject": {
                "text": "by 49%"
            },
            "object": {
                "text": "infection"
            },
            "action": {
                "text": "documented",
                "lemmatized": "document",
                "verb": {
                    "text": "document",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " 1991. In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[6] A 2002 meta-analysis found that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%.[7]",
            "subject": {
                "text": "the risk of infection-related mortality"
            },
            "object": {
                "text": "by 40%"
            },
            "action": {
                "text": "reduced",
                "lemmatized": "reduce",
                "verb": {
                    "text": "reduce",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " 2010. On June 6, 2010 Amgen received FDA approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.[10] In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.[11]",
            "subject": {
                "text": "2010 Amgen"
            },
            "object": {
                "text": "FDA approval"
            },
            "action": {
                "text": "received",
                "lemmatized": "receive",
                "verb": {
                    "text": "receive",
                    "tense": "past"
                }
            }
        },
        {
            "location": {
                "text": "In clinical trials"
            },
            "sentence": " 2010. On June 6, 2010 Amgen received FDA approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.[10] In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.[11]",
            "subject": {
                "text": "Prolia"
            },
            "object": {
                "text": "the rate of vertebral fractures"
            },
            "action": {
                "text": "reduced",
                "lemmatized": "reduce",
                "verb": {
                    "text": "reduce",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " 2010 In November 2010 the FDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.[12] The clinical trials primarily enrolled patients with breast or prostate cancer.",
            "subject": {
                "text": "the FDA"
            },
            "object": {
                "text": "Xgeva for the prevention of complications of bone metastases in patients with solid tumors.[12] The clinical trials"
            },
            "action": {
                "text": "approved",
                "lemmatized": "approve",
                "verb": {
                    "text": "approve",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " The Los Angeles Times reported on December 18, 2012, that AMGEN pled guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints.",
            "subject": {
                "text": "The Los Angeles Times"
            },
            "object": {
                "text": "that AMGEN pled guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints"
            },
            "action": {
                "text": "reported",
                "lemmatized": "report",
                "verb": {
                    "text": "report",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " The Los Angeles Times reported on December 18, 2012, that AMGEN pled guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints.",
            "subject": {
                "text": "AMGEN"
            },
            "object": {
                "text": "to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints"
            },
            "action": {
                "text": "agreed",
                "lemmatized": "agree",
                "verb": {
                    "text": "agree",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " The Los Angeles Times reported on December 18, 2012, that AMGEN pled guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints.",
            "subject": {
                "text": "AMGEN"
            },
            "object": {
                "text": "$150 million in criminal penalty and $612 million"
            },
            "action": {
                "text": "agreed to pay",
                "lemmatized": "agree to pay",
                "verb": {
                    "text": "pay",
                    "tense": "future"
                }
            }
        },
        {
            "sentence": " 2012. Amgen paid $762 million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs.[16]",
            "subject": {
                "text": "2012. Amgen"
            },
            "object": {
                "text": "$762 million"
            },
            "action": {
                "text": "paid",
                "lemmatized": "pay",
                "verb": {
                    "text": "pay",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " 2012. Amgen paid $762 million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs.[16]",
            "subject": {
                "text": "2012. Amgen"
            },
            "object": {
                "text": "guilty"
            },
            "action": {
                "text": "pleading",
                "lemmatized": "plead",
                "verb": {
                    "text": "plead",
                    "tense": "present"
                }
            }
        },
        {
            "sentence": " 2013. Lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes Sensipar without government controls for an additional two years.",
            "subject": {
                "text": "the fiscal cliff bill"
            },
            "object": {
                "text": "to sell a class of drugs that includes Sensipar without government controls for an additional two years"
            },
            "action": {
                "text": "will allow",
                "lemmatized": "will allow",
                "verb": {
                    "text": "allow",
                    "tense": "future"
                }
            }
        },
        {
            "sentence": " 2013. Lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes Sensipar without government controls for an additional two years.",
            "subject": {
                "text": "the drugmaker"
            },
            "object": {
                "text": "a class of drugs that includes Sensipar without government controls"
            },
            "action": {
                "text": "to sell",
                "lemmatized": "to sell",
                "verb": {
                    "text": "sell",
                    "tense": "future"
                }
            }
        },
        {
            "sentence": " 2013. Lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes Sensipar without government controls for an additional two years.",
            "subject": {
                "text": "Sensipar without government controls"
            },
            "object": {
                "text": "a class of drugs"
            },
            "action": {
                "text": "includes",
                "lemmatized": "include",
                "verb": {
                    "text": "include",
                    "tense": "present"
                }
            }
        },
        {
            "sentence": " The New York Times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million[17] but other assessments concluded that the change would protect seniors in rural areas and reduce overall Medicare spending.[18] [19]",
            "subject": {
                "text": "The New York Times"
            },
            "object": {
                "text": "that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million"
            },
            "action": {
                "text": "estimated",
                "lemmatized": "estimate",
                "verb": {
                    "text": "estimate",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " The New York Times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million[17] but other assessments concluded that the change would protect seniors in rural areas and reduce overall Medicare spending.[18] [19]",
            "subject": {
                "text": "the paragraph in the fiscal cliff bill"
            },
            "object": {
                "text": "an estimated $500 million"
            },
            "action": {
                "text": "will cost",
                "lemmatized": "will cost",
                "verb": {
                    "text": "cost",
                    "tense": "future"
                }
            }
        },
        {
            "sentence": " The New York Times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million[17] but other assessments concluded that the change would protect seniors in rural areas and reduce overall Medicare spending.[18] [19]",
            "subject": {
                "text": "other assessments"
            },
            "object": {
                "text": "that the change would protect seniors in rural areas and reduce overall Medicare spending.[18] [19]"
            },
            "action": {
                "text": "concluded",
                "lemmatized": "conclude",
                "verb": {
                    "text": "conclude",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " The New York Times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million[17] but other assessments concluded that the change would protect seniors in rural areas and reduce overall Medicare spending.[18] [19]",
            "subject": {
                "text": "the change"
            },
            "object": {
                "text": "overall Medicare spending."
            },
            "action": {
                "text": "reduce",
                "lemmatized": "reduce",
                "verb": {
                    "text": "reduce",
                    "tense": "present"
                }
            }
        },
        {
            "sentence": " 2015. In September the company announced it would acquire Dezima Pharma for more than $1.55 billion.[20] The same day the company announced a collobaration with Xencor on 6 early stage immuno-oncology and inflammation programmes.",
            "subject": {
                "text": "2015. In September the company"
            },
            "object": {
                "text": "it would acquire Dezima Pharma for more than $1.55 billion.[20] The same day the company announced a collobaration with Xencor on 6 early stage immuno-oncology and inflammation programmes"
            },
            "action": {
                "text": "announced",
                "lemmatized": "announce",
                "verb": {
                    "text": "announce",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " As part of the deal Amgen will pay $45 million upfront, with the deal being worth up to another $1.7 billion.[21] [22]",
            "subject": {
                "text": "Amgen"
            },
            "object": {
                "text": "$45 million upfront"
            },
            "action": {
                "text": "will pay",
                "lemmatized": "will pay",
                "verb": {
                    "text": "pay",
                    "tense": "future"
                }
            }
        },
        {
            "sentence": " As part of the deal Amgen will pay $45 million upfront, with the deal being worth up to another $1.7 billion.[21] [22]",
            "subject": {
                "text": "the deal"
            },
            "object": {
                "text": "worth up to another $1.7 billion.[21] [22]"
            },
            "action": {
                "text": "being",
                "lemmatized": "be",
                "verb": {
                    "text": "be",
                    "tense": "present"
                }
            }
        },
        {
            "sentence": " As of December, 2013, Amgen had twelve approved drugs or therapeutic biologicals for seventeen conditions (conditions lists are highly generalized; see each article for more detail):",
            "subject": {
                "text": "Amgen"
            },
            "object": {
                "text": "twelve approved drugs or therapeutic biologicals for seventeen conditions (conditions lists are highly generalized"
            },
            "action": {
                "text": "had",
                "lemmatized": "have",
                "verb": {
                    "text": "have",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " Epogen (Epoetin) (also known as Procrit; for anemia)",
            "subject": {
                "text": "Epogen (Epoetin)"
            },
            "object": {
                "text": "as Procrit"
            },
            "action": {
                "text": "also known",
                "lemmatized": "also know",
                "verb": {
                    "text": "know",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " As of December 2013, Amgen had 11 drugs in Phase III clinical trials.[44]",
            "subject": {
                "text": "Amgen"
            },
            "object": {
                "text": "11 drugs in Phase III clinical trials."
            },
            "action": {
                "text": "had",
                "lemmatized": "have",
                "verb": {
                    "text": "have",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " In November 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.[45] Later in the same week, the company (in conjunction with AstraZeneca) reported positive results for brodalumab in a phase ||| trial comparing the compound with ustekinumab and a placebo in treating psoriasis.[46]",
            "subject": {
                "text": "the company"
            },
            "object": {
                "text": "it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.[45] Later in the same week, the company (in conjunction with AstraZeneca) reported positive results for brodalumab in a phase ||| trial comparing the compound with ustekinumab and a placebo in treating psoriasis.[46]"
            },
            "action": {
                "text": "announced",
                "lemmatized": "announce",
                "verb": {
                    "text": "announce",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " In November 2014 the company announced it was halting all trials of rilotumumab in advanced gastric cancer patients after one of the trials found more deaths in those who took the compound with chemotherapy, than those without.[45] Later in the same week, the company (in conjunction with AstraZeneca) reported positive results for brodalumab in a phase ||| trial comparing the compound with ustekinumab and a placebo in treating psoriasis.[46]",
            "subject": {
                "text": "those"
            },
            "object": {
                "text": "the compound"
            },
            "action": {
                "text": "took",
                "lemmatized": "take",
                "verb": {
                    "text": "take",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " In March 2015, the company announced it would licence its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[47]",
            "subject": {
                "text": "the company"
            },
            "object": {
                "text": "it would licence its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[47]"
            },
            "action": {
                "text": "announced",
                "lemmatized": "announce",
                "verb": {
                    "text": "announce",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " In March 2015, the company announced it would licence its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[47]",
            "subject": {
                "text": "developer Celimmune"
            },
            "object": {
                "text": "to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[47]"
            },
            "action": {
                "text": "plan",
                "lemmatized": "plan",
                "verb": {
                    "text": "plan",
                    "tense": "present"
                }
            }
        },
        {
            "sentence": " In March 2015, the company announced it would licence its Phase II candidate drug AMG 714 to developer Celimmune who plan to develop the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[47]",
            "subject": {
                "text": "developer Celimmune"
            },
            "object": {
                "text": "the anti-IL-15 monoclonal antibody for treatment against diet nonresponsive celiac disease and refractory celiac disease.[47]"
            },
            "action": {
                "text": "plan to develop",
                "lemmatized": "plan to develop",
                "verb": {
                    "text": "develop",
                    "tense": "future"
                }
            }
        },
        {
            "sentence": " ^ a b c d e f \"Amgen Inc., Form 10-K, Annual Report, For the Fiscal Year Ended December 31, 2014, Filing Date Feb 19, 2015\".",
            "subject": {
                "text": "the Fiscal Year"
            },
            "action": {
                "text": "Ended",
                "lemmatized": "Ended",
                "verb": {
                    "text": "Ended",
                    "tense": "past"
                }
            }
        },
        {
            "sentence": " ^ \"FDA approves Xgeva to help prevent cancer-related bone injury\".",
            "subject": {
                "text": "FDA"
            },
            "object": {
                "text": "Xgeva"
            },
            "action": {
                "text": "approves",
                "lemmatized": "approve",
                "verb": {
                    "text": "approve",
                    "tense": "present"
                }
            }
        }
    ],
    "usage": "By accessing AlchemyAPI or using information generated by AlchemyAPI, you are agreeing to be bound by the AlchemyAPI Terms of Use: http://www.alchemyapi.com/company/terms.html",
    "status": "OK",
    "url": ""
}